Bulletin
Investor Alert

New York Markets Close in:

DaVita Inc.

NYS: DVA

GO
/marketstate/country/us

Market open

 --Real time quotes

Apr 8, 2020, 9:41 a.m.

DVA
/zigman2/quotes/204229673/composite

$

73.00

Change

+1.01 +1.40%

Volume

Volume 7,800

Real time quotes

/zigman2/quotes/204229673/composite

Previous close

$ 71.99

$ 73.00

Change

+1.01 +1.40%

Day low

Day high

$72.34

$73.24

Open

52 week low

52 week high

$43.40

$90.15

Open

Company Description

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United...

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Valuation

P/E Current

13.47

P/E Ratio (with extraordinary items)

11.43

P/E Ratio (without extraordinary items)

14.23

Price to Sales Ratio

1.01

Price to Book Ratio

4.43

Price to Cash Flow Ratio

5.56

Enterprise Value to EBITDA

8.65

Enterprise Value to Sales

1.80

Total Debt to Enterprise Value

0.49

Efficiency

Revenue/Employee

175,207.00

Income Per Employee

10,874.00

Receivables Turnover

4.84

Total Asset Turnover

0.61

Liquidity

Current Ratio

1.56

Quick Ratio

1.51

Cash Ratio

0.51

Profitability

Gross Margin

25.10

Operating Margin

15.41

Pretax Margin

10.50

Net Margin

6.21

Return on Assets

3.78

Return on Equity

24.22

Return on Total Capital

11.78

Return on Invested Capital

5.72

Capital Structure

Total Debt to Total Equity

523.85

Total Debt to Total Capital

83.97

Total Debt to Total Assets

61.82

Long-Term Debt to Equity

501.61

Long-Term Debt to Total Capital

80.40

Officers and Executives

Name Age Officer Since Title
Mr. Kent J. Thiry 63 1999 Executive Chairman
Mr. Javier J. Rodriguez 48 1998 Chief Executive Officer & Director
Mr. Atul Mathur - 2011 President-Asia Pacific Region
Mr. Joel Ackerman 54 2017 Chief Financial Officer
Ms. LeAnne M. Zumwalt 60 2000 Vice President-Purchasing & Public Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/20/2020 Pamela M. Arway
Director
625   Disposition at $71.25 per share. 44,531
03/16/2020 Berkshire Hathaway, Inc. (Investment Management)
470,000   0
03/15/2020 Peter Thacher Grauer
Director
913   Award at $0 per share. 0
03/15/2020 Kathleen Alyce Waters
Chief Legal Officer
14,483   Award at $0 per share. 0
03/15/2020 John M. Nehra
Director
625   Award at $0 per share. 0
03/15/2020 Pamela M. Arway
Director
625   Award at $0 per share. 0
03/15/2020 Charles G. Berg
Director
625   Award at $0 per share. 0
03/15/2020 LeAnne M. Zumwalt
Group VP, Government Affairs
1,646   Award at $0 per share. 0
03/15/2020 William L. Roper
Director
625   Award at $0 per share. 0
03/15/2020 Paul J. Diaz
Director
625   Award at $0 per share. 0
03/15/2020 James O. Hearty
Chief Compliance Officer
2,304   Award at $0 per share. 0
03/15/2020 Barbara J. Desoer
Director
625   Award at $0 per share. 0
03/15/2020 Phyllis R. Yale
Director
625   Award at $0 per share. 0
03/15/2020 John David Winstel
Chief Accounting Officer
1,580   Award at $0 per share. 0
03/15/2020 Pascal Desroches
Director
625   Award at $0 per share. 0
03/04/2020 John M. Nehra
Director
125   Gift at $0 per share. 0
03/03/2020 John M. Nehra
Director
189   Gift at $0 per share. 0
03/02/2020 John M. Nehra
Director
7,694   Disposition at $80.74 per share. 621,213
02/27/2020 John M. Nehra
Director
11,806   Disposition at $80.49 per share. 950,264
02/26/2020 John M. Nehra
Director
20,000   Disposition at $80.93 per share. 1,618,600
02/26/2020 John M. Nehra
Director
240   Gift at $0 per share. 0
12/20/2019 John M. Nehra
Director
200   Gift at $0 per share. 0
12/10/2019 John M. Nehra
Director
290   Gift at $0 per share. 0
/news/latest/company/us/dva

MarketWatch News on DVA

  1. DaVita's new positions include care giving to corporate support

    6:20 a.m. April 2, 2020

    - Tomi Kilgore

  2. DaVita to hire 15,000 new employees through 2020

    6:20 a.m. April 2, 2020

    - Tomi Kilgore

  3. DaVita stock price target raised to $91 from $74 at UBS

    10:40 a.m. Feb. 12, 2020

    - Tomi Kilgore

  4. The Stock Market Is Rising Because Jerome Powell Is On the Job

    2:01 p.m. Feb. 11, 2020

    - Barron's Online

  5. DaVita stock price target raised to $105 from $72 at Deutsche Bank

    7:56 a.m. Feb. 11, 2020

    - Tomi Kilgore

  6. Podcast: This Week’s Earnings Highlights

    6:02 a.m. Feb. 10, 2020

    - Barron's Online

  7. Nvidia, Lyft, Alibaba, and Other Stocks to Watch This Week

    4:00 p.m. Feb. 9, 2020

    - Barron's Online

  8. Under Armour Works on Its Comeback

    10:30 p.m. Feb. 7, 2020

    - Barron's Online

  9. A Late-Year Recovery Saved UnitedHealth Stock

    9:00 a.m. Dec. 29, 2019

    - Barron's Online

  10. 19 Stocks That Are On a Roll — and Still Cheap

    11:46 a.m. Dec. 23, 2019

    - Barron's Online

  11. DaVita stock price target raised to $75 from $65 at J.P. Morgan

    9:18 a.m. Dec. 20, 2019

    - Tomi Kilgore

  12. DaVita stock price target raised to $80 from $72 at SunTrust RH

    8:52 a.m. Dec. 18, 2019

    - Tomi Kilgore

  13. DaVita stock price target raised to $82 from $75 at BofA Merrill Lynch

    10:41 a.m. Dec. 6, 2019

    - Tomi Kilgore

  14. DaVita downgraded to market perform from outperform at Raymond James

    9:10 a.m. Nov. 7, 2019

    - Tomi Kilgore

  15. Jim Chanos unveils short position in kidney-dialysis firm DaVita

    12:33 p.m. Sept. 19, 2019

    - Chris Matthews

  16. Loading more headlines...
/news/nonmarketwatch/company/us/dva

Other News on DVA

  1. Maybe We Can Climb The Great Wall Of Worry

    3:47 p.m. April 7, 2020

    - Seeking Alpha

  2. Should Value Investors Buy DaVita HealthCare (DVA) Stock?

    11:50 a.m. April 6, 2020

    - Zacks.com

  3. 5 Stocks to Buy for 5 Good Reasons

    4:33 p.m. April 3, 2020

    - Zacks.com

  4. 5 Top Value Stocks to Buy in a Volatile April

    6:53 a.m. April 2, 2020

    - Zacks.com

  5. DVA or CHE: Which Is the Better Value Stock Right Now?

    11:40 a.m. April 1, 2020

    - Zacks.com

  6. Has DaVita (DVA) Outpaced Other Medical Stocks This Year?

    11:30 a.m. April 1, 2020

    - Zacks.com

  7. Top Ranked Growth Stocks to Buy for March 31st

    10:36 a.m. March 31, 2020

    - Zacks.com

  8. Job Hazard: Employees Don Masks, Meet Resistance

    6:30 a.m. March 25, 2020

    - Te-Ping Chen

  9. DVA vs. CHE: Which Stock Should Value Investors Buy Now?

    11:40 a.m. March 16, 2020

    - Zacks.com

  10. Loading more headlines...

At a Glance

DaVita, Inc.

2000 16th Street

Denver, Colorado 80202-7198

Phone

1 7206312100

Industry

Healthcare Provision

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$11.39B

Net Income

$706.83M

Employees

65,000

/news/pressrelease/company/us/dva

Press Releases on DVA

  1. DaVita Hiring 15,000 New Teammates Nationwide

    6:17 a.m. April 2, 2020

    - PR Newswire - PRF

  2. Focus on Patient Care Brings Industry Together to Fight Crisis

    5:01 p.m. March 31, 2020

    - PR Newswire - PRF

  3. DaVita Supports 55,000 Teammates amid COVID-19 Crisis

    5:21 p.m. March 23, 2020

    - PR Newswire - PRF

  4. DaVita Hospital Services Group Names New Chief Medical Officer

    6:14 a.m. March 11, 2020

    - PR Newswire - PRF

  5. Loading more headlines...
Link to MarketWatch's Slice.